Imipenem Levels are Not Predictable in the Critically III Patient

Journal of Trauma - Injury, Infection and Critical Care

Volumn 56, Issue 1, 2004, Pages 111-117

  Belzberg, Howard ^a   Zhu, Jay ^a   Cornwell III, Edward E ^c   Murray, James A ^a   Sava, Jack ^a   Salim, Ali ^a   Velmahos, George C ^a   Gill, Mark A ^b  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Imipenem; Sepsis Therapeutic levels; Septic shock; Systemic inflammatory distress syndrome; Volume of distribution

Indexed keywords

IMIPENEM;

ADULT; AGED; CLINICAL ARTICLE; CONFERENCE PAPER; CRITICAL ILLNESS; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0842300407     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TA.0000056164.26493.28     Document Type: Conference Paper

References (19)

1. Clissold S, Todd P, Campoli-Richards D. Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1987;33:183-241.
2. Kahan F, Rogers J. Imipenem/cilastatin: evolution of the sustained-release intramuscular formulation. Chemotherapy. 1991;37:21-25.
3. Fabian T, Hess M, Croce M, et al. Superiority of aztreonam/clindamycin compared with gentamicin/clindamycin in patients with penetrating abdominal trauma. Am J Surg. 1994;167:291-296.
4. Solomkin JS, Dellinger E, Christou N, et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg. 1990;212:581-591.
5. McKindley D, Fabian T, Boucher B, et al. Antibiotic pharmacokinetics following fluid resuscitation from traumatic shock. Arch Surg. 1995;130:1321-1329.
6. Erttmann M, Krausse R, Ullmann U. Pharmacokinetics of imipenem in patients undergoing major colon surgery. Infection. 1990;18:367-371.
7. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis. 1993;21:172-179.
8. LeGall J, Lemeshow S, Saulnier F, et al. A new simplified acute physiology score (SAPS II) based on the European/North American multicenter study. JAMA. 1993;270:2957-2963.
9. Boucher BA, Hickerson W, Kuhl D, et al. Imipenem pharmacokinetics in patients with burns. Clin Pharmacol Ther. 1990;48:130-137.
10. Rocci M, Jusko W. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983;16:203-216.
11. Bauer LA, Gibaldi M. Computation of model independent pharmacokinetic parameters during multiple dosing. J Pharm Sci. 1983;72:978-979.
12. Bergan T, Micalson H, Malmborg A, et al. Pharmacokinetic evaluation of imipenem combined with cilastatin in cystic fibrosis. Chemotherapy. 1993;39:369-373.
13. Cornwell EE III, Belzberg H, Berne TV, et al. Pharmacokinetics of aztreonam therapy in critically ill surgical patients. Am J Health Syst Pharm. 1997;54:537-541.
14. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993;37:1073-1081.
15. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-12.
16. Drusano GL, Standiford HC, Bustamente C, et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 1984;26:715-721.
17. Bone R, Fisher C, Clemmer T, et al. Sepsis syndrome: a valid clinical entity. Crit Care Med. 1989;17:389-393.
18. MacGregor R, Gibson G, Bland J. Imipenem pharmacokinetics and body fluid concentrations in patients receiving high dose treatment for serious infections. Antimicrob Agents Chemother. 1986;29:188-192.
19. Cornwell EE III, Belzberg H, Berne TV, et al. Aminoglycoside levels in critically ill surgical patients: the implications of physiologic criteria of sepsis. South Med J. 1997;90:33-36.